

PROTEOMICS BASED SENSITIVE QUANTITATIVE PREDICTIONS OF MHC BINDING PEPTIDE FROM *TAENIA OVIS*

GOMASE V.S.* AND CHITLANGE N.R.

Department of Bioinformatics, Jagdishprasad Jhabarmal Tibrewala University, Jhunjhunu Rajasthan, 333001,

*Corresponding author. E-mail: gomase.viren@gmail.com

Received: June 14, 2011; Accepted: July 01, 2011

Abstract- The sheep ingests an egg. The egg hatches in the small intestine and the larval tapeworm burrows through the intestinal wall and travel to the heart and muscles via the blood. The cysticercus develop in the cardiac and skeletal muscles, reaching the infective stage in about 46 days. When the dog eats the sheep and ingests the cysticercus, the protoscolex attaches to the small intestinal wall and the worm begins to form proglottids. Peptide fragments of antigen protein can be used to select nonamers for use in rational vaccine design and to increase the understanding of roles of the immune system in infectious diseases. Analysis shows MHC class II binding peptides of antigen protein from *Taenia ovis* are important determinant for protection of host from parasitic infection. In this assay, we used PSSM and SVM algorithms for antigen design and predicted the binding affinity of antigen protein having 238 amino acids, which shows 231 nonamers. Binding ability prediction of antigen peptides to major histocompatibility complex (MHC) class I & II molecules is important in vaccine development from *Taenia ovis*.

Keywords- antigen protein, epitope, PSSM, SVM, MHC, peptide vaccine

Abbreviations: Goldman, Engelberg and Steitz, (GES); major histocompatibility complex, (MHC); Position Specific Scoring Matrices, (PSSMs); Support Vector Machine, (SVM)

I. Introduction

Taenia ovis antigen peptides are most suitable for subunit vaccine development because with single epitope, the immune response can be generated in large population [1,2]. This approach is based on the phenomenon of cross-protection, whereby infected with a mild strain and is protected against a more severe strain of the same. The phenotype of the resistant transgenic hosts includes fewer centers of initial infection, a delay in symptom development, and low accumulation. Antigen protein from *Taenia ovis* is necessary for new paradigm of synthetic vaccine development and target validation [3-5].

II. Methodology

In this research work antigenic epitopes of antigen protein from *Taenia ovis* is determined using the Gomase in 2007, Welling, Eisenberg, Parker and Chou & Fasman and Levitt antigenicity [6-8]. The major histocompatibility complex (MHC) peptide binding of antigen protein is predicted using neural networks trained on C terminals of known epitopes. In analysis predicted MHC/peptide binding of antigen protein is a log-transformed value related to the IC50 values in nM units. MHC2Pred predicts peptide binders to MHC I and MHC II molecules from protein sequences or sequence alignments using Position Specific Scoring Matrices (PSSMs). Support Vector Machine (SVM) based method for prediction of promiscuous MHC class II binding peptides. SVM has been trained on the binary input of single amino acid sequence [9-14]. In addition, we predict those MHC ligands from whose C-terminal end is likely to be the result of proteosomal cleavage [15-18].

III. Results and Interpretations

We found binding of peptides to a number of different alleles using Position Specific Scoring Matrix. An antigen protein sequence is 44 residues long, having antigenic MHC binding peptides. MHC molecules are cell surface glycoproteins, which take active part in host immune reactions and involvement of MHC class-I and MHC II in response to almost all antigens. PSSM based server predict the peptide binders to MHC I molecules of antigen protein sequence are as 11mer_H2_Db, 10mer_H2_Db, 9mer_H2_Db, 8mer_H2_Db and also peptide binders to MHC II molecules of antigen protein sequence as I_Ab.p, I_Ad.p, analysis found antigenic epitopes region in putative antigen protein (Table 1). We also found the SVM based MHC II-IAb peptide regions; MHC II-IAd peptide regions; MHC II-IAg7 peptide regions and MHC II- RT1.B peptide regions, which represented predicted binders from bacterial antigen protein (Table 2). The predicted binding affinity is normalized by the 1% fractil. We describe an improved method for predicting linear epitopes (Table 2). The region of maximal hydrophilicity is likely to be an antigenic site, having hydrophobic characteristics, because terminal regions of antigen protein is solvent accessible and unstructured, antibodies against those regions are also likely to recognize the native protein (Fig. 1, 2, 3). It was shown that a antigen protein is hydrophobic in nature and contains segments of low complexity and high-predicted flexibility (Fig. 4, 5). Predicted antigenic fragments can bind to MHC molecule is the first bottlenecks in vaccine design.

IV. Conclusion

An antigen protein from *Taenia ovis* peptide nonamers are from a set of aligned peptides known to bind to a given MHC molecule as the predictor of MHC-peptide binding. MHCII molecules bind peptides in similar yet different modes and alignments of MHCII-ligands were obtained to be consistent with the binding mode of the peptides to their MHC class, this means the increase in affinity of MHC binding peptides may result in enhancement of immunogenicity of antigen protein. These predicted of antigen protein antigenic peptides to MHC class molecules are important in vaccine development from *Taenia ovis*.

V. References

- [1] Jabbar A., Kyngdon C.T., Gauci C.G., Walduck A.K., McCowan C., Jones M.K., Beveridge I., Lightowers M.W. (2010) *Int J Parasitol*, 40(5):579-89.
- [2] Jabbar A., Crawford S., Gauci C.G., Walduck A.K., Anderson G.A., Lightowers M.W. (2010) *Infect Immun*, 78(10):4363-73.
- [3] Dadley-Moore D.L., Lightowers M.W., Rothel J.S., Jackson D.C. (1999) *Vaccine*, 17(11-12):1506-15.
- [4] McDonald D., Stockwin L., Matzow T., Blair Zajdel M.E., Blair G.E. (1999) *Gene Ther*, 6(9),1512-9.
- [5] Gomase V.S., Kale K.V. and Shyamkumar K. (2008) *J. of Proteomics & Bioinformatics*, 1 (4), 188- 205.
- [6] Gomase V.S., Kale K.V., Chikhale N.J., Changbhale S.S. (2007) *Curr. Drug Discov. Technol.*, 4(2),117-1215.
- [7] Gomase V.S. and Kale K.V. (2008) *Int. J. of Applied Computing*, 1(1), 39-46.
- [8] Gomase V.S. and Kale K.V. (2008) *Int. J. of Applied Computing*, 1(1), 33-38.
- [9] Gomase V.S. and Kale K.V. (2008) *Int. J. of Information Retrieval*, 1(1), 11-15.
- [10] Gomase V.S., Kale K.V., Shyamkumar K. and Shankar S. (2008) *ICETET 2008, IEEE Computer Society in IEEE Xplore, Los Alamitos, California*, 629-634.
- [11] Gomase V.S., Tandale J.P., Patil S.A., Kale K.V. (2006) *14th International Conference on Advance Computing & Communication, Published by IEEE Computer Society in IEEE Xplore USA* 614-615.
- [12] Reche P.A., Glutting J.P., Reinherz E.L. (2002) *Hum Immun.*, 63, 701-709.
- [13] Buus S., et al. (2003) *Tissue Antigens*, 62, 378-384.
- [14] Nielsen M., et al. (2003) *Protein Sci.*, 12, 1007-1017.
- [15] Bhasin M. and Raghava G.P. (2005) *Nucleic Acids Research*, 33, W202-207.
- [16] Gomase V.S., Kapoor R.A., Ladak S.S. (2010) *Journal of Infectious Diseases Letters*, 1(1), 01-06.
- [17] Gomase V.S. and Shyamkumar K. (2009) *African Journal of Biotechnology*, 8 (23), 6658-6676.
- [18] Gomase V.S., Kapoor R.A., Ladak S.S. (2010) *Software and Computing Technology, ICSCCT 2010, IEEE Computer Society in IEEE Xplore, USA*.

Table 1- PSSM based prediction of MHC ligands, from whose C-terminal end are proteosomal cleavage sites

MHC-I	POS.	N	Sequence	C	MW (Da)	Score	% OPT.
8mer_H2_Db	220	LNE	LEEDFRTI	LSI	1004.12	16.314	31.08 %
8mer_H2_Db	95	RQV	AOYNNFSI	FSK	938.01	13.407	25.54 %
8mer_H2_Db	44	ICQ	FNLRCLEF	LKS	1023.23	9.894	18.85 %
8mer_H2_Db	38	KAV	PSLICQFN	LRC	903.07	9.7	18.48 %
8mer_H2_Db	139	DHL	PINPEVKI	SNG	891.08	8.916	16.98 %
8mer_H2_Db	322	PVS	RKAGPMTY	QML	905.08	8.704	16.58 %
8mer_H2_Db	96	QVA	QYNNFSIF	SKK	1014.11	8.63	16.44 %
9mer_H2_Db	63	EMY	FMLCLIDHI	ISN	1086.38	20.064	39.84 %
9mer_H2_Db	95	RQV	AOYNNFSIF	SKK	1085.19	19.926	39.56 %
9mer_H2_Db	130	MEL	FAHWSKDHL	PIN	1099.25	19.277	38.27 %
9mer_H2_Db	44	ICQ	FNLRCLEFL	KSY	1136.39	15.072	29.93 %
9mer_H2_Db	41	PSL	ICQFNLRCL	EFL	1091.36	13.216	26.24 %
9mer_H2_Db	38	KAV	PSLICQFNL	RCL	1016.23	11.437	22.71 %
9mer_H2_Db	184	GVD	QLIKNAREL	YTE	1066.27	11.399	22.63 %
10mer_H2_Db	306	VSP	SILKPLADYG	ILN	1058.25	22.969	39.02 %
10mer_H2_Db	94	FRQ	VAQYNNFSIF	SKK	1184.32	19.021	32.32 %
10mer_H2_Db	73	HII	SNYEPFRKGF	ATK	1226.37	16.158	27.45 %
10mer_H2_Db	95	RQV	AOYNNFSIFS	KKN	1172.27	16.055	27.28 %
10mer_H2_Db	206	SIF	NGEINEKEKA	ELN	1113.19	15.416	26.19 %
10mer_H2_Db	9	LVK	SAIDNEEVNP	SLH	1069.1	11.88	20.18 %
10mer_H2_Db	70	LID	HIISNYEPFR	KGF	1257.43	11.82	20.08 %
11mer_H2_Db	94	FRQ	VAQYNNFSIFS	KKN	1271.4	13.696	17.23 %
11mer_H2_Db	285	DYS	KTETNYESYPV	QRE	1312.4	10.441	13.13 %
11mer_H2_Db	322	PVS	RKAGPMTYQML	EDD	1277.56	9.568	12.04 %
11mer_H2_Db	57	SYI	SRKEMYFMLCL	IDH	1402.76	9.078	11.42 %
11mer_H2_Db	39	AVP	SLICQFNLRCL	EFL	1291.6	7.777	9.78 %
11mer_H2_Db	8	ELV	KSAIDNEEVNP	SLH	1197.27	6.901	8.68 %
11mer_H2_Db	58	YIS	RKEMYFMLCLI	DHI	1428.84	6.462	8.13 %

Table 2- SVM based prediction of promiscuous MHC class II binding peptides from antigen protein

MHC ALLELE	Rank	Sequence	Residue No.	Peptide Score
I-Ab	1	TLKAVPTSE	49	0.965
I-Ab	2	VPTSEPNTT	53	0.882
I-Ab	3	RTLKSGHKE	202	0.866
I-Ab	4	PTSEPNTTK	54	0.855
I-Ad	1	ETSALIVTL	139	0.703
I-Ad	2	NATYLVATAT	81	0.632
I-Ad	3	GIASITLGL	220	0.625
I-Ad	4	ASTILGLLL	222	0.589
I-Ag7	1	TKTAYAKLG	61	1.687
I-Ag7	2	YLVATANI	84	1.587
I-Ag7	3	DIFAWEPPT	19	1.499
I-Ag7	4	RTVVEYPSL	9	1.377
RT1.B	1	TKTAYAKLG	61	1.063
RT1.B	2	NNTKTAYAK	59	0.842
RT1.B	3	TWQRHAFPG	34	0.709
RT1.B	4	NTKTAYAKL	60	0.626




Fig. 1- Hydrophobicity plot of antigen protein by Hphob / Welling & al., scale




Fig. 2- Hydrophobicity plot of antigen protein by Hphob/ Eisenberg, et al., scale




Fig. 3- Hydrophobicity plot of antigen protein by Hphob. HPLC /Parker & et al., scale




Fig. 4- Antigenicity plot of antigen protein by Hphob. / Rao & Argos, scale




Fig. 5- Antigenicity plot of antigen protein by Hphob. / Manavalan et al., scale